BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|October 1, 2006
- Volume 0 0
GENERIC FIRMS AGREE TO OXYCONTIN SETTLEMENT
Advertisement
Teva Pharmaceuticals andEndo Pharmaceutical HoldingsInc will halt sales of genericOxyContin (oxycodone) by theend of this year under a settlementagreement resolvingpatent disputes with PurduePharma. Under the terms ofthe agreement, the genericcompanies will not be heldliable for any past or futureinfringement of Purdue'spatents for the painkiller.
The settlements mark thelatest in a series of legal twiststhat began with a June 2005ruling that several OxyContinpatents were unenforceablebecause of misrepresentationsby the patentee. Thatdecision opened the door forthe marketing of generic versionsof the drug, but thatopportunity evaporated whenthe courts reconsidered thecase and sent the case back totrial for further review.
Articles in this issue
about 20 years ago
Equation for Success: Diabetes Medication, Diet, and Exerciseabout 20 years ago
Rx Product Newsabout 20 years ago
OTC Product Newsabout 20 years ago
can you READ these Rxs?about 20 years ago
Juvenile Anabolic Steroid Abuseabout 20 years ago
Compounding Hotlineabout 20 years ago
RESPy AWARD: A Role Model for Pharmacy Studentsabout 20 years ago
Ouch! Time for Flu Shotsabout 20 years ago
Supreme Court Declines to Review Generic Marketing PactsAdvertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
2
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5